ATE448788T1 - Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen - Google Patents

Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen

Info

Publication number
ATE448788T1
ATE448788T1 AT04778892T AT04778892T ATE448788T1 AT E448788 T1 ATE448788 T1 AT E448788T1 AT 04778892 T AT04778892 T AT 04778892T AT 04778892 T AT04778892 T AT 04778892T AT E448788 T1 ATE448788 T1 AT E448788T1
Authority
AT
Austria
Prior art keywords
methylene
vitamin
inflammatory bowel
bowel disease
compounds
Prior art date
Application number
AT04778892T
Other languages
German (de)
English (en)
Inventor
Hector Deluca
Margherita Cantorna
Original Assignee
Wisconsin Alumni Res Found
Penn State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found, Penn State Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of ATE448788T1 publication Critical patent/ATE448788T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04778892T 2003-10-08 2004-07-23 Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen ATE448788T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/680,881 US7704980B2 (en) 2003-10-08 2003-10-08 Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
PCT/US2004/023586 WO2005039592A1 (en) 2003-10-08 2004-07-23 Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin d compounds

Publications (1)

Publication Number Publication Date
ATE448788T1 true ATE448788T1 (de) 2009-12-15

Family

ID=34422197

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04778892T ATE448788T1 (de) 2003-10-08 2004-07-23 Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen

Country Status (10)

Country Link
US (2) US7704980B2 (enExample)
EP (1) EP1673095B1 (enExample)
JP (1) JP2007508298A (enExample)
AT (1) ATE448788T1 (enExample)
AU (1) AU2004283073B2 (enExample)
CA (1) CA2541991A1 (enExample)
DE (1) DE602004024221D1 (enExample)
ES (1) ES2338428T3 (enExample)
NZ (1) NZ546440A (enExample)
WO (1) WO2005039592A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2764577C (en) * 2009-08-03 2017-12-19 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
US20110237557A1 (en) * 2010-03-23 2011-09-29 Deluca Hector F Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
US8604009B2 (en) * 2010-03-23 2013-12-10 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
FR2961401B1 (fr) * 2010-06-17 2013-04-05 Laetitia Mathez Composition anti-inflammatoire
CN102631354B (zh) * 2011-02-11 2015-01-21 广东泰禾医药科技有限公司 含维生素d3和二甲双胍的药物组合物
WO2012166938A2 (en) 2011-06-03 2012-12-06 Wisconsin Alumni Research Foundation (22e)-2-methylene-26,27-cyclo-22-dehydro-1alpha-hydroxy-19-norvitamin d3 derivatives
US20130295083A1 (en) * 2012-05-02 2013-11-07 Wisconsin Alumni Research Foundation 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes
HK1206600A1 (en) 2012-06-29 2016-01-15 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM
US9370527B2 (en) 2012-12-28 2016-06-21 The Regents Of The University Of Michigan Amelioration of intestinal fibrosis and treatment of Crohn's disease
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
WO2017184262A1 (en) * 2016-04-18 2017-10-26 Wisconsin Alumni Research Foundation Use of 2amd and 2md to treat fibrosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4221961A1 (de) 1992-06-30 1994-01-05 Schering Ag 22-En-25-oxa-Derivate in der Vitamin D-Reihe, Verfahren zu ihrer Herstellung, diese Derivate enthaltenen pharmazeutische Präparate sowie deren Verwendung als Arzneimittel
IL107185A (en) 1992-10-06 1998-02-22 Schering Ag Vitamin d, 25-carboxylic acid derivatives and pharmaceutical compositions containing the same
US5981597A (en) * 1995-02-13 1999-11-09 Trustees Of The University Of Pennsylvania Differentiating agents for the treatment of inflammatory intestinal diseases
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US6358939B1 (en) * 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) * 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6806262B2 (en) * 2000-05-31 2004-10-19 Wisconsin Alumni Research Foundation 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds
AU7544501A (en) * 2000-09-08 2002-03-22 Wisconsin Alumni Res Found 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
WO2003051828A2 (en) * 2001-12-13 2003-06-26 Wisconsin Alumni Research Foundation (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
US7259143B2 (en) * 2002-09-05 2007-08-21 Wisconsin Alumni Research Foundation Method of extending the dose range of vitamin D compounds

Also Published As

Publication number Publication date
DE602004024221D1 (de) 2009-12-31
AU2004283073A1 (en) 2005-05-06
ES2338428T3 (es) 2010-05-07
US20100160267A1 (en) 2010-06-24
NZ546440A (en) 2009-08-28
EP1673095B1 (en) 2009-11-18
EP1673095A1 (en) 2006-06-28
JP2007508298A (ja) 2007-04-05
WO2005039592A1 (en) 2005-05-06
US7704980B2 (en) 2010-04-27
US20050080059A1 (en) 2005-04-14
CA2541991A1 (en) 2005-05-06
AU2004283073B2 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
NZ591362A (en) Multiple-variable dose regimen for treating tnfa-related disorders
GB0225474D0 (en) Therapeutic agents
ATE448788T1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen
GB0223038D0 (en) Therapeutic compounds
NO20014842D0 (no) Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft
SE8903914D0 (sv) Oral composition for the treatment of inflammatory bowel diseases
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
ATE281839T1 (de) Behandlung des kongestiven herzversagens durch vorbehandeltes autologes blut
DE60144514D1 (de) Verwendung von il-18 inhibitoren
WO2020186132A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
NO20060913L (no) Behandling av avhengighetsabstinens
ATE536178T1 (de) Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
EA200801731A1 (ru) Составы и способы лечения тробмоцитемии
BRPI0517976A (pt) métodos de tratamento
ATE447426T1 (de) Elektromagnetische stimulation bei patienten mit osteoporose
RU2006113366A (ru) Терапевтическое лечение
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
ATE410172T1 (de) Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
DE60206280D1 (de) Verwendung von extrakten aus ginkgo biloba zur herstellung eines medikaments zur behandlung von sarcopenia
HUP0203486A2 (hu) Véralvadással összefüggő betegségek megelőzése és kezelése
AU2003283227A8 (en) Method and means for the treatment of vascular and cardiac diseases
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties